| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2017-06-03 | AG-120 (ivosidenib) isocitrate dehydrogenase 1 (IDH1)-mutant inhibitor | IDH1 gene-mutated cholangiocarcinoma | 3 | Agios Pharmaceuticals (USA -MA) | Cancer - Oncology - Rare diseases |
| 2017-06-03 | LOXO- 101 (larotrectinib - (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | pediatric patients with advanced solid or primary central nervous system tumors | 1 | Loxo Oncology (USA - CT) | Cancer - Oncology |
| 2017-06-03 | abemaciclib (LY2835219) | hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer | 3 | Eli Lilly (USA - IN) | Cancer - Oncology |
| 2017-06-03 | LOXO- 101 (larotrectinib - (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate | NTRK fusion-positive tumors | 2 | Loxo Oncology (USA - CT) | Cancer - Oncology |
| 2017-06-03 | Xilonix™ | advanced colorectal cancer | 3 | XBiotech (USA - TX) | Cancer - Oncology |
| 2017-06-02 | Opdivo® (nivolumab) | advanced cervical, vaginal and vulvar cancers associated with infection by the human papillomavirus (HPV). | 1-2 | BMS (USA - NY) | Cancer - Oncology |
| 2017-06-02 | MOR208 plus bendamustine | patients with relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT) | 2-3 | MorphoSys (Germany) | Cancer - Oncology |
| 2017-06-01 | BioChaperone® Glucagon | type 1 diabetes | 1 | Adocia (France) | Metabolic diseases |
| 2017-06-01 | BioChaperone® Lispro U100 with Fiasp® (faster-acting insulin aspart) and Novolog®(insulin aspart) | type 1 diabetes | 1 | Adocia (France) | Metabolic diseases |
| 2017-06-01 | C-Scape (ACHN-383 and ACHN-789) | 1 | Achaogen (US - CA) | Infectious diseases | |
| 2017-06-01 | luspatercept | beta-thalassemia | 3 | Celgene (USA - NJ) Acceleron Pharma (USA - CA) | Rare diseases - Genetic diseases - Hematological diseases |
| 2017-06-01 | luspatercept | myelodysplastic syndromes (MDS) | 3 | Celgene (USA - NJ) Acceleron Pharma (USA - MA) | Cancer - Oncology - Rare diseases - Genetic diseases |
| 2017-05-31 | RGX-314 | wet age-related macular degeneration (wet AMD) | 1 | RegenXBio (USA - MD) | Ophtalmological diseases |
| 2017-05-30 | MP0250 | multiple myeloma | 2 | Molecular Partners (Switzerland) | Cancer - Oncology |
| 2017-05-30 | SYL1001 (tivanisiran) | dry eye syndrome | 3 | Sylentis (Spain) | Ophtalmological diseases |
| 2017-05-30 | LOXO-195 | cancers that have acquired resistance to initial TRK therapy | 1-2 | Loxo Oncology (USA - CT) | Cancer - Oncology |
| 2017-05-30 | mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) | observational | Lysogene (France) | Rare diseases - Genetic diseases | |
| 2017-05-27 | doravirine (MK-1439) | HIV-1 infection | 3 | Merck&Co (USA - NJ) | Infectious diseases |
| 2017-05-27 | Ofev® (nintedanib) | idiopathic pulmonary fibrosis (IPF) | 3 | Boehringer Ingelheim (Germany) | Lung diseases - Respiratory diseases |
| 2017-05-25 | NY-ESO SPEAR T-cells targeting NY-ESO in combination with Keytruda® (pembrolizumab) | relapsed and/or refractory multiple myeloma | 1 | Adaptimmune (UK) | Cancer - Oncology |
